Commentary: Tackling the challenges of developing targeted therapies for cancer

Oncologist

Volumn 15, Issue 5, 2010, Pages 484-487

  Schilsky, Richard L ^a   Allen, Jeff ^b   Benner, Joshua ^c   Sigal, Ellen ^b   McClellan, Mark ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b Friends of Cancer Research   (United States)

^c BROOKINGS INSTITUTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC ERROR;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 77952623379     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0079     Document Type: Article

References (6)

1. Amit O, Bushnell W, Dodd L et al. Blinded independent central review of the progression-free survival endpoint. The Oncologist 2010;15:492-495.
2. Chapman P, Puzanov I, Sosman J et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 (abstract 6LB). Eur J Cancer Suppl 2009;7(3):5
3. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non small cell lung cancer to gefitinib. New Engl J Med 2005;352:786-792.
4. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non small cell lung can- cer. Clin Cancer Res 2008;14:2895-2899.
5. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads togefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
6. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-1508.